|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||89.04 - 89.32|
|52-week range||89.04 - 89.32|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.
Tandem Diabetes Care today announced its acquisition of Sugarmate, a popular mobile app for people with diabetes who use insulin.
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Tandem Diabetes Care announces expanded pediatric indication for t:slim X2 insulin pump with Control-IQ technology.
Tandem presents positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Kathleen McGroddy-Goetz, Ph.D., as an independent member of its Board of Directors effective June 8, 2020. Dr. McGroddy-Goetz has extensive experience commercializing pioneering technologies spanning from microelectronics through cloud, advanced data analytics, AI, hardware, software, and middleware with an emphasis on healthcare and life sciences applications.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders ("Annual Meeting") will be held in a virtual-only format due to continued public health concerns relating to COVID-19 and to prioritize the health and well-being of meeting participants. There is no change to the previously announced date and time of the meeting, which will be held on May 27, 2020 at 3:00pm Pacific Daylight Time.
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem" or, the "Company") announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes. The sale of the Notes is expected to close on May 15, 2020, subject to customary closing conditions.